|Dr. Isaac E. Ciechanover||Pres, CEO & Director||883.57k||N/A||1971|
|Mr. Joseph Newell||Exec. VP & Chief Technical Operations Officer||624.67k||N/A||1970|
|Dr. Derrell D. Porter||Sr. VP & Global Commercial Head||458.15k||N/A||1971|
|Mr. Utpal Koppikar||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Christopher M. Haqq||Exec. VP of R&D & Chief Scientific Officer||N/A||N/A||1966|
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It is also developing ATA188 and autologous ATA190 that are in Phase I clinical trials for the treatment of multiple sclerosis; ATA520, a Phase I clinical trial product to treat Wilms tumor 1; and ATA230, which is Phase II clinical trials for refractory cytomegalovirus. In addition, the company is developing ATA368 that is under preclinical development for HIV and cancers. It has license agreements with Memorial Sloan Kettering Cancer Center and Amgen, Inc.; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with Moffitt Cancer Center. The company was founded in 2012 and is headquartered in South San Francisco, California.
Atara Biotherapeutics, Inc.’s ISS Governance QualityScore as of January 1, 2019 is 9. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 7; Compensation: 10.